Tom Frohlich insider trades
Open-market stock purchases and sales by Tom Frohlich, Chief Executive Officer at Jade Biosciences, Inc, from SEC Form 4 filings since Oct 5, 2020.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +101%.